Abstract
Lymphoid malignancies typically promote an infiltrate of immune cells at sites involved by the disease. While some of the immune cells present in lymphoma have effector function, the immune system is unable to eradicate the malignant clone. Therapies that optimize immune function therefore have the potential to improve the outcome of lymphoma patients. In this Review, we discuss immunologic approaches that directly target the malignant cell as well as approaches to optimize both the innate and adaptive immune response to the tumor. While many of these therapies have shown single-agent activity, the future will clearly require thoughtful combinations of these approaches.
Original language | English (US) |
---|---|
Pages (from-to) | 1576-1585 |
Number of pages | 10 |
Journal | Journal of Clinical Investigation |
Volume | 130 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1 2020 |
ASJC Scopus subject areas
- General Medicine